|
Operating profit increased significantly / Strong sales of new products are expected in the second half of the year (based on the half-year financial disclosure)
2018.08.14
|
|---|
|
Daehan New Pharm announced that its consolidated operating profit for the first half of 2018 reached 9.46 billion won, representing a 44% increase compared to the same period the previous year. Sales slightly decreased to 61.469 billion won, and net loss amounted to 3.881 billion won due to increased other expenses.
The company has been strengthening its market position recently with the launch of the non-reimbursed injection ‘Same injection’ and plans to release the anticancer adjunct ‘Thymosin Injection.’ In July, Daehan New Pharm signed an exclusive sales contract for the next-generation premium dissolvable thread ‘TESSLIFTSOFT.’
Demand for the livestock stress reliever ‘Power GABA-C’ surged due to the record heatwave. Power GABA-C is user-friendly and proven effective against stress, dehydration, and reproductive disorders, with demand already exceeding production plans.
Continuous efforts to improve financial structure and optimize costs are showing positive results. The new injection ‘Same injection’ and the upcoming anticancer adjunct ‘Thymosin Injection’ are expected to contribute to sales growth in the second half, supported by active seminars and online/offline promotions. |


Home